产品
编 号：F626240
分子式：C25H36N4O10
分子量：552.57
分子式：C25H36N4O10
分子量：552.57
产品类型
规格
价格
是否有货
结构图
CAS No: 1207859-16-2
产品详情
生物活性：
Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia.
体内研究：
Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model.Animal Model:Male Wistar rats with gastric ulceration
Dosage:0.25-1 mg/kg
Administration:Intraperitoneal injection; 0.25-1 mg/kg; once
Result:Reduced haemorrhagic lesions compared with the ulcerated control group.Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg).Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01).Increased GSH-px activity in the gastric mucosa.
Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia.
体内研究：
Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model.Animal Model:Male Wistar rats with gastric ulceration
Dosage:0.25-1 mg/kg
Administration:Intraperitoneal injection; 0.25-1 mg/kg; once
Result:Reduced haemorrhagic lesions compared with the ulcerated control group.Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg).Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01).Increased GSH-px activity in the gastric mucosa.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备